Candriam Luxembourg S.C.A. held its position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 118,000 shares of the biotechnology company’s stock at the end of the second quarter. Candriam Luxembourg S.C.A.’s holdings in Aurinia Pharmaceuticals were worth $723,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Renaissance Technologies LLC purchased a new position in shares of Aurinia Pharmaceuticals during the first quarter worth $776,000. AWM Investment Company Inc. purchased a new position in shares of Aurinia Pharmaceuticals during the first quarter worth $2,202,000. Morgan Stanley raised its position in shares of Aurinia Pharmaceuticals by 11,061.7% in the first quarter. Morgan Stanley now owns 446,135 shares of the biotechnology company’s stock worth $3,273,000 after buying an additional 442,138 shares in the last quarter. UBS Group AG raised its position in shares of Aurinia Pharmaceuticals by 13.6% in the first quarter. UBS Group AG now owns 112,314 shares of the biotechnology company’s stock worth $824,000 after buying an additional 13,405 shares in the last quarter. Finally, Monashee Investment Management LLC purchased a new position in shares of Aurinia Pharmaceuticals during the first quarter worth $1,835,000. 30.29% of the stock is currently owned by institutional investors and hedge funds.

Shares of Aurinia Pharmaceuticals Inc (NASDAQ AUPH) opened at 6.17 on Tuesday. The firm’s market capitalization is $513.79 million. Aurinia Pharmaceuticals Inc has a one year low of $1.88 and a one year high of $10.54. The firm has a 50-day moving average price of $6.32 and a 200 day moving average price of $6.23.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.10. The firm had revenue of $0.33 million during the quarter, compared to the consensus estimate of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 38.20% and a negative net margin of 16,648.93%. Equities analysts forecast that Aurinia Pharmaceuticals Inc will post ($0.74) earnings per share for the current fiscal year.

WARNING: “Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Stake Maintained by Candriam Luxembourg S.C.A.” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.watchlistnews.com/aurinia-pharmaceuticals-inc-nasdaqauph-stake-maintained-by-candriam-luxembourg-s-c-a/1488958.html.

A number of research analysts have recently weighed in on the company. HC Wainwright cut their price objective on Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday, May 18th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $14.00 target price on shares of Aurinia Pharmaceuticals in a report on Friday, April 21st. Vetr lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.74 target price on the stock. in a report on Monday, July 31st. BidaskClub lowered Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Finally, Zacks Investment Research lowered Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, June 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $9.28.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP).

Institutional Ownership by Quarter for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.